(Q47563820)

14 June 2018

title

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia (English)

1 reference

14 June 2018

main subject

phase I clinical trial

0 references

author

Phoenix A Ho

13

1 reference

14 June 2018

Stefan Faderl

11

Stefan Faderl

1 reference

14 June 2018

7

Farhad Ravandi

1 reference

14 June 2018

6

Jeffrey E Lancet

1 reference

14 June 2018

Anjali S Advani

5

Anjali S Advani

1 reference

14 June 2018

Harry P Erba

3

Harry P Erba

1 reference

14 June 2018

Roland B Walter

2

Roland B Walter

1 reference

14 June 2018

Daniel J DeAngelo

9

Daniel J DeAngelo

1 reference

14 June 2018

Tibor Kovacsovics

8

Tibor Kovacsovics

1 reference

14 June 2018

author name string

Eytan M Stein

1

1 reference

14 June 2018

Amir T Fathi

4

1 reference

14 June 2018

Dale Bixby

10

1 reference

14 June 2018

Anand P Jillella

12

1 reference

14 June 2018

Megan M O'Meara

14

1 reference

14 June 2018

Baiteng Zhao

15

1 reference

14 June 2018

Charles Biddle-Snead

16

1 reference

14 June 2018

Anthony S Stein

17

1 reference

14 June 2018

language of work or name

English

0 references

publication date

1 December 2017

1 reference

14 June 2018

published in

Blood

1 reference

14 June 2018

volume

131

1 reference

14 June 2018

issue

4

1 reference

14 June 2018

page(s)

387-396

1 reference

14 June 2018

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5813721

14 June 2018

Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5813721

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5813721

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5813721

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5813721

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5813721

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5813721

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5813721

The past and future of CD33 as therapeutic target in acute myeloid leukemia.

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5813721

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5813721

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

16 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5813721

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5813721

10.1182/BLOOD-2017-06-789800

14 August 2018

Identifiers

DOI

1 reference

14 June 2018

PMC publication ID

5813721

1 reference

14 June 2018

PubMed publication ID

29196412

1 reference

14 June 2018